ArticleActas espanolas de psiquiatria2025
The Combined Effects of EEG Biofeedback and Olanzapine on Glucose and Lipid Metabolism, Cardiac Function, and Cognitive Function in Patients With Schizophrenia.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia (SCZ) is a chronic mental disorder characterized by severe impairments in the daily functioning and social interactions of the patient. Compared to conventional pharmacological interventions, electroencephalogram (EEG) biofeedback offers stable and sustained effects and reduces susceptibility to relapse. This study aimed to investigate the impact of EEG biofeedback combined with olanzapine (OLZ) on glucose and lipid metabolism, cardiac function, and cognitive ability in SCZ patients.
methodsA retrospective analysis was conducted on the medical records of 66 SCZ patients who received treatment at Taizhou Second Peoples' Hospital between June 2023 and March 2024. The patients were categorized into groups based on their treatment regimens: a single group (n = 30) and a combined therapy group (EEG biofeedback + OLZ, n = 36). Treatment efficacy and adverse reactions were compared between the groups. Key parameters assessed included glucose and lipid metabolism [total cholesterol (TC), triglyceride (TG), and fasting plasma glucose (FPG)], electrocardiographic (ECG) findings [T-wave changes, ST-segment changes, sinus bradycardia, sinus tachycardia, and other abnormalities], symptom severity [Positive and Negative Syndrome Scale (PANSS)], and cognitive function [Insight and Treatment Attitudes Questionnaire (ITAQ)] before and after treatment.
resultsThe total effective rate in the combined therapy group (91.67%) was significantly higher than in the single group (73.33%) (p < 0.05). Post-treatment, both groups exhibited significantly lower TC and FPG levels and higher TG levels compared to pre-treatment values (p < 0.05). However, no significant differences were observed between groups in these metabolic indices (p > 0.05). Similarly, no significant differences in ECG abnormalities were detected between groups, either pre- or post-treatment (p > 0.05). The combined therapy group demonstrated significantly greater improvements in general psychopathological symptoms, positive symptoms, negative symptoms, and PANSS scores, as well as significantly higher ITAQ scores compared to the single group (p < 0.05). The incidence of adverse reactions did not significantly differ between the single group (6.67%) and the combined therapy group (13.89%) (p > 0.05).
conclusionEEG biofeedback combined with OLZ improves psychiatric symptoms and cognitive function of SCZ patients compared to OLZ monotherapy. Notably, the combined therapy does not exacerbate ECG abnormalities, metabolic indices, or adverse reactions, indicating a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.